<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804581</url>
  </required_header>
  <id_info>
    <org_study_id>University of Khartoum</org_study_id>
    <nct_id>NCT02804581</nct_id>
  </id_info>
  <brief_title>Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients</brief_title>
  <official_title>Potential Role of Gum Arabic as Immunomodulator In Sudanese Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lamis Kaddam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Neelain University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gum Arabic (GA) rich dietary fiber it is a water-soluble dietary fiber derived from the dried
      gummy exudates of the stems and branches of Acacia senegal, GA found to have strong immuno
      modulator in vitro where it increased IL10 production showing strong anti-inflammatory
      effects (19).

      The aim of this study is to determine the role of gum Arabic in immunomodulation among
      patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Butyrate is short chain fatty acids representing the most important end product of colonic
      bacterial aerobic fermentation of Gum Arabic , it has a potent anti-inflammatory effect and
      can down regulates TNF a expression by modulating NF-kB-DNA binding activity , in addition
      butyrate is known to act as histone deacetylase inhibitor in the cells.Recently, in vitro and
      in vivo data indicates that HDAC inhibitors may have anti-inflammatory effect due to their
      effects on cell death acting through acetylation of non-histone proteins. The possible
      anti-rheumatic mechanisms of HDAC inhibitors, including growth arrest in rheumatoid arthritis
      synovial fibroblasts (RASFs), suppression of pro-inflammatory cytokines, suppressing
      angiogenesis as well as the protective effects on bone and cartilage against their
      destruction.

      The investigators expect regular intake of GA will raise serum butyrate level. The endogenous
      butyrate decreases the TNF level. The latter will decrease the number of relapsing episodes,
      arresting the destruction of joints and improve both survival and life quality of rheumatoid
      arthritis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of C reactive protein (CRP)and Tumer necrosis factor alpha TNF</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical improvement</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total anti-oxidant capacity (TAC), malondialdehyde (MDA) and hydrogen peroxide (H2O2) level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Gum Arabic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of 30 gram of Gum Arabic daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gum Arabic</intervention_name>
    <description>Oral intake of GA in powder from30 grams per day</description>
    <arm_group_label>Gum Arabic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of Rheumatoid Arthritis

          2. Clinically stable as evidenced by medical history, complete physical examination

          3. All medications and dosages are stable for 6 weeks before study entry,

          4. Non Pregnant ladies.

        Exclusion Criteria:

          -  1- hepatic, cardiovascular, pulmonary, malignant, hematologic, neurologic, infectious,
             or inflammatory diseases unrelated to Rheumatoid arthritis.

             2-Hospital admission within 4 weeks of start of the study.

             3- Uncontrolled hypertension 4- Asthma or severe atopic disease;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alnour Alagib, MBBS,MD,MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amal M Saeed, MBBS,PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Khartoum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ebtihal K Obied, MBBS</last_name>
    <phone>. 00249912279229</phone>
    <email>E.Kamal.Ali@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lamis AM Kaddam, MBBS,PhD</last_name>
    <phone>00249912979736</phone>
    <email>lamiskaddam@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Military Hospital Rheumatology</name>
      <address>
        <city>Khartoum</city>
        <state>Umdorman</state>
        <zip>1121</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alnour Elagib, MBBS,MRCP,MD</last_name>
      <phone>00249912306262</phone>
      <email>elagib62@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ebtihal Obied, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alnour Elagib, MBBS,MRCP,MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <reference>
    <citation>Xuan NT, Shumilina E, Nasir O, Bobbala D, GÃ¶tz F, Lang F. Stimulation of mouse dendritic cells by Gum Arabic. Cell Physiol Biochem. 2010;25(6):641-8. doi: 10.1159/000315083. Epub 2010 May 18.</citation>
    <PMID>20511709</PMID>
  </reference>
  <reference>
    <citation>Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 2007 Apr;150(7):829-31. Epub 2007 Feb 26.</citation>
    <PMID>17325655</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Al-Neelain University</investigator_affiliation>
    <investigator_full_name>Lamis Kaddam</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Factors</mesh_term>
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

